Acinetobacter baumannii is a gram-negative organism reported worldwide as a cause of health-care associated infections. Due to its increasing drug resistance, several studies on coproduction of armA and carbapenemase in South Korea and other parts of the world were reported, which can pose significant therapeutic threat. The aim of this study was to investigate genetic characteristics of multidrug-resistant A. baumannii coproducing armA and carbapenemase and its epidemiological relatedness. Forty-five multidrug resistant (MDR) A. baumannii clinical isolates were collected. Antimicrobial susceptibility was determined by agar dilution, Etest and VITEK 2 system. The presence of 16S rRNA methylase and carbapenemase were analyzed by polymerase chain reaction (PCR) and sequencing. Repetitive element palindromic (REP)-PCR was also performed for epidemiologic investigation. All of A. baumannii isolates harbored bla OXA-51 -like gene and 10 isolates showed an upstream ISAba1. 36 isolates (80%) showed amplification of OXA-23, all of which except one had an upstream ISAba1. 16S rRNA methylase armA was found in 44 isolates with high level resistance to aminoglycosides. The rate of coproduction was found in 36 isolates (80%). All isolates showed dominant two patterns in REP-PCR profile. The prevalence of MDR A. baumannii coproducing OXA-23 and armA was high, which the rate of bla OXA-23 coproduction was also high.
INTRODUCTION
Acinetobacter baumannii is a gram-negative organism reported worldwide as a cause of health-care associated infections, particularly in intensive care units (ICUs) (1) . It is responsible for pneumonia, urinary tract infections, skin and soft tissue infections, and bloodstream infections (2) . Despite intensive efforts, nosocomial acquisition of multidrug resistant (MDR) A. baumannii is still a problem due to its great ability to disseminate from and colonize human and environmental reservoir (3, 4) . carbapenemase-encoding gene (6) .
Aminoglycoside antibiotics are frequently ineffective against strains of A. baumannii, but are nevertheless used together with carbapenems to treat infected patients because the two agents have synergistic effects (7) . Resistance to amino glycosides is most commonly encountered by amino glycoside-modifying enzymes, including acetylaminotransferases, nucleotidyltransferase, and phosphotransferases (8) .
But recently the production of 16S rRNA methylases has been implicated in aminoglycoside resistance among the gram-negative pathogens (9) . They were found to confer extraordinarily high levels of resistance to clinically useful aminoglycosides, such as amikacin, tobramycin and gentamicin, which thus effectively eliminating the entire class as a therapeutic option (9, 10) . The dissemination of different types of 16S rRNA methylase were found in different bacterial species or regions (11~14) but armA has been the only 16S rRNA methylase found in A. baumannii (14~16).
Recently in several studies of A. baumannii coproducing armA and carbapenemase in South Korea (16, 17) and other parts of the world were reported (10, 18, 19) , which can pose significant therapeutic threat.
The aim of this study was to describe the genetic characteristics of MDR A. baumannii coproducing armA and carbapenemase and to investigate the genetic relatedness through epidemiologic study.
MATERIAL AND METHODS

Identification of A. baumannnii
Isolates identified as A. baumannnii or Acinetobacter spp. by the VITEK2 (bioMérieux, Marcy l'Etoile, France) automated microbiology system were collected between January 2012 and November 2012 from Chungnam National University Hospital. Identification of A. baumannnii was confirmed by rpoB gene analysis (20) . Genomic DNA was obtained from each target strain by using the genomic DNA purification kit (Solgent, Daejeon, South Korea) according to the standard protocols. 
Determination of minimal inhibitory concentrations (MICs)
RESULTS
Identification of bacterial strains and antibiotic susceptibility testing
A total of 45 isolates were confirmed as A. baumannii by The MICs of other antimicrobials were listed in Table 2 .
Genetic characterization of MDR A. baumannii
All A. baumannii harbored bla OXA-51 -like gene which is intrinsic beta-lactamase to A. baumannii ( isolates (82.2%) and they were highly resistant to carbapenems and aminoglycosides. And besides they were also resistant to ciprofloxacin, cefepime, azteronam and piperacillin/tazobactam while susceptible to minocycline and colistin.
REP-PCR patterns
The 45 isolates showed dominantly 2 types (A and B) of REP-PCR patterns, while a few showed C types (Fig. 1) . 
DISCUSSION
MICs were determined by Etest (bioMérieux, Marcy l'Etoile, France). But MICs of antimicrobials except Amikacin, gentamicin, tobramycin, imipenem and meropenem were determined by VITEK 2 system (bioMérieux, Marcy l'Etoile, France) in isolates in red color. Abbreviations: MIC, minimal inhibitory concentration; CIP, ciprofloxacin; MN, minocycline; CS, colistin; AN, amikacin; GEN, gentamicin; TOB, tobramycin; IMP, imipenem, MEM, meropenem, FEP, cefepime, P/T, piperacillin/tazobactam; AZ, azteronam. showing susceptibility to amikacin. In our study, the rate of very major error (false susceptibility) was 77.3% (34 out of 44 isolates), which was much higher than previous report (36.4%) (31). Jung et al. (32) reported false susceptibility to amikacin by VITEK2 in A. baumannii was related to harboring armA but in our study almost all isolates harbored armA and some of them showed concordant result with reference method. Thus susceptibility testing error can occur regardless of harboring armA but tend to occur more often in MDR A. buamannii. So additional testing for susceptibility to amikacin in MDR A. baumannii may not be necessary for confirmation.
In conclusion, our study showed 16S rRNA methylase armA and carbapenemase OXA-23 was highly prevalent in MDR A. baumannii. Due to its patient to patient transfer in the spread of antimicrobial resistance as shown in REP-PCR, the needs for hospitals to isolate and screen for MDR pathogens and more strict infection control are pivotal for preventing further dissemination. The high prevalence of MDR isolates coproducing armA and bla OXA-23 can also threaten therapeutic options for these infections.
